| glucosidase inhibitor | Agents such as acarbose which reduce gastrointestinal absorption of carbohydrates. This group of drugs has been known popularly as "starch blockers". They lower plasma glucose levels and tend to cause weight loss. A limiting side effect is flatulence. (05 Mar 2000) |
|---|---|
| medication, ace-inhibitor | Agents that inhibit ACE (angiotensin-converting enzyme), thereby acting as vasodilators (really as anti-vasoconstrictors), lightening the stress load on the heart. (12 Dec 1998) |
| residual inhibitor | A sound-generating device, worn in the ear, which inhibits or suppresses the sounds of tinnitus by masking, with a residual inhibitory effect when the device is turned off. (05 Mar 2000) |
| respiratory inhibitor | A compound that inhibits the respiratory chain. Synonym: respiratory poison. (05 Mar 2000) |
| cholinesterase inhibitor | <pharmacology> These are substances which which act to inhibit acetylcholinesterase, the enzyme which breaks down acetylcholine and thus enhance and subsequently prevent transmission of nerve impulses from one nerve cell to another or to a muscle. Examples include pyridostigmine, ambenonium and neostigmine. (15 Jan 1998) |
| monoamine oxidase inhibitor | <pharmacology> A drug that interferes with the action of monoamine oxidase, slowing the breakdown of certain neurotransmitters. Used in the treatment of depression. Monoamine oxidase inhibitors are a group of antidepressant drugs that prevent the activity of the enzyme monoamine oxidase in the central nervous system (brain) thus affecting mood. The use of these medications is often restricted due to their severe side effects and drug (and food) interactions. Examples include isocarboxazid, pargyline, selegiline, furazolidone and phenelzine. Acronym: MAOI (26 Mar 1998) |
| complement cytolysis inhibitor | <protein> Vertebrate glycoprotein of uncertain function. Secreted as a 400 amino acid peptide, then cleaved to form two 200 amino acid peptides that are linked by a disulphide bridge. Synonym: complement associated protein, complement cytolysis inhibitor, glycoprotein III. (11 Jan 1998) |
| plasminogen activator inhibitor 1 | <chemical> A member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activator. Pharmacological action: serine proteinase inhibitors. (12 Dec 1998) |
| plasminogen activator inhibitor 2 | <chemical> Member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activator. Pharmacological action: serine proteinase inhibitors. (12 Dec 1998) |
| cyclooxygenase inhibitor | <pharmacology> Compounds or agents that combine with cyclooxygenase (prostaglandin-endoperoxide synthase) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes. (08 Mar 2000) |
| proteinase inhibitor inducing factor | See: PIIF. (18 Nov 1997) |
| protein c inhibitor | <chemical> A member of the serpin family of proteins that is found in plasma and urine. It is dependent on heparin and able to inhibit activated protein c, thrombin, kallikrein, and other serine proteinases. Pharmacological action: serine proteinase inhibitors. (12 Dec 1998) |
| protein synthesis inhibitor | Compounds which inhibit the synthesis of proteins. They are usually antibiotics or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the the a site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (12 Dec 1998) |
| proton pump inhibitor | <pharmacology> A group of anti-ulcer medications which work by binding to H+/K+ ATPase, an enzyme which is found on the secretory surface of parietal cells. It thereby inhibits the final transport of hydrogen ions (via exchange with potasium) into the gastric lumen. Examples of proton pump inhibitors include omeprazole and lansoprazole. (27 Sep 1997) |
| HMG CoA reductase inhibitor | Drugs, such as lovastatin and pravastatin, which interfere with the biosynthesis of cholesterol; used to treat hyperlipidemia. (05 Mar 2000) |